corporate overview

• Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.


• Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.


• Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates.


• Current product development programs include fostamatinib (previously R788), an oral syk inhibitor that is in its phase 3 clinical trial program (OSKIRA) for rheumatoid arthritis (w/partner AstraZeneca), R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma, R333, a topical JAK/SYK inhibitor for the treatment of discoid lupus and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.